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Complement activation is an important contributor to
the inflammatory response to CPB,1,2 but the pathways
linking specific complement components to secondary
mediators are incompletely defined. Complement acti-
vation generates the proinflammatory and procoagulant
moieties C3a and C5a and the membrane attack com-
plex (MAC), C5b-9, whereas other neutral or anti-
inflammatory components (eg, the opsonin C3b) are
essential for normal immune function.3
In vitro studies have demonstrated a number of com-
plement-mediated proinflammatory and procoagulant
effects relevant to CPB. Generation of the MAC
induces platelet a -granule release,4 platelet prothrombi-
nase activity,5 and platelet expression of CD62P,6 which
mediates the binding of activated platelets to leuko-
cytes.7 We have demonstrated an increase in platelet
CD62P during clinical CPB,8 as well as a parallel
increase in circulating monocyte-platelet conjugates.9,10
T he systemic inflammatory response to cardiopul-monary bypass (CPB) results in humoral and cellu-
lar changes contributing to clinical complications.
Objective: Complement activation is induced by cardiopulmonary
bypass, and previous work found that late complement components
(C5a, C5b-9) contribute to neutrophil and platelet activation during
bypass. In the present study, we blocked C5b-9 formation during extra-
corporeal recirculation of whole blood to assess whether the membrane
attack complex was responsible for both platelet and leukocyte activa-
tion. Methods: In a simulated extracorporeal model that activates com-
plement (C3a and sC5b-9), platelets (CD62P expression, leukocyte-
platelet conjugate formation), and leukocytes (increased CD11b
expression and neutrophil elastase), we examined an anti-human C8
monoclonal antibody that inhibits C5b-9 generation for its effects on cel-
lular activation. Results: Anti-C8 significantly inhibited sC5b-9 forma-
tion but did not block C3a generation. Anti-C8 also significantly inhib-
ited the increase in platelet CD62P and monocyte-platelet conjugate
formation seen with control circulation. Moreover, compared with con-
trol circulation, in which the number of circulating platelets fell by 45%,
addition of anti-C8 completely preserved platelet counts. In contrast to
blockade of both C5a and sC5b-9 during simulated extracorporeal cir-
culation, neutrophil activation was not inhibited by anti-C8. However,
circulating neutrophil and monocyte counts were preserved by addition
of anti-C8 to the extracorporeal circuit. Conclusions: The membrane
attack complex, C5b-9, is the major complement determinant of platelet
activation during extracorporeal circulation, whereas C5b-9 blockade
has little effect on neutrophil activation. These data also suggest a role
for platelet activation or C5b-9 (or both) in the loss of monocytes and
neutrophils to the extracorporeal circuit. (J Thorac Cardiovasc Surg
1999;118:460-6)
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C5a formation up-regulates neutrophil (PMN)
CD11b/CD18 through mobilization of intracellular
granules,11 a marker of leukocyte activation that we
have demonstrated to occur on both PMNs and mono-
cytes during clinical CPB.10 Both C5a and C5b-9 also
promote endothelial cell CD62P expression in vitro.12
In vitro recirculation of whole blood in an extracor-
poreal bypass circuit, for example, simulated extracor-
poreal circulation (SECC), has been used extensively to
simulate platelet,13 leukocyte,14 and complement acti-
vation15 on CPB. It serves as a preclinical model for
examining the response of human blood to interven-
tions targeting inflammatory or coagulopathic compli-
cations of CPB. Novel interventions blocking comple-
ment activation at different stages now allow us to
selectively examine the pathophysiology of cell-medi-
ated, complement-dependent responses to extracorpo-
real circulation. We15 have previously demonstrated
that simultaneous blockade of both C5a and the MAC
prevented both platelet and PMN activation during
SECC. In the current study, we used a blocking mono-
clonal antibody (Mab) directed against the complement
component C8 to examine the specific role of the MAC
on platelet and PMN activation during SECC.
Methods
Materials. A murine Mab directed against the human com-
plement component C8 (clone 133.3) developed by Dr P.
Sims was supplied by Alexion Pharmaceuticals (New Haven,
Conn). Control Mab directed against mouse C5 (clone
BB5.1) was the gift of Dr Brigitta Stockinger. All Mabs for
fluorescence labeling were used as purified whole im-
munoglobulin G. Anti-CD41a recognizes platelet glycopro-
tein IIb/IIIa; this Mab and anti-CD62P were purchased from
Pharmingen (San Diego, Calif). For leukocyte labeling, anti-
CD45 (Pharmingen) and anti-CD11b (ExAlpha, Boston,
Mass) were used.
In vitro studies16 had demonstrated that the anti-C8 Mab at
30 m g/mL completely inhibited C5b-9 generation in human
serum (measured both by a functional hemolytic assay and by
enzyme-linked immunosorbent assay) without significant
blockade of either C3a or C5a generation. Preliminary dosing
studies indicated that anti-C8 at 40 m g/mL in whole blood
was the lowest dose giving maximal C5b-9 blockade during
SECC, and thus 40 m g/mL was used in the present study. In
vitro whole blood experiments demonstrated that this dose of
anti-C8 Mab had no direct effect on either platelet or leuko-
cyte activation. The anti-C8 Mab did not inhibit platelet
CD62P expression to a 1 m mol/L dose of epinephrine fol-
lowed by a 5 m mol/L dose of adenosine diphosphate, nor the
increase in CD11b on monocytes and PMNs in response to a
1 m mol/L dose of N-formyl-methionyl-leucyl-phenylalanine.
Extracorporeal circuit preparation. As previously
described, extracorporeal circuits were assembled with the
use of a pediatric membrane oxygenator (VP CML Plus:
Cobe Cardiovascular, Arvada, Colo) and a roller pump
(Cardiovascular Instruments Corp, Wakefield, Mass). The
oxygenator and circuitry were primed with lactated Ringer’s
solution containing dextrose (4.0 g/L), mannitol (4.0 g/L),
and porcine heparin (5 U/mL) and circulated at 1.5 L/min
with sweep gas flow (95% oxygen, 5% carbon dioxide) at
0.25 L/min. The pH, PO2, and temperature were continuous-
ly monitored and maintained at a pH of 7.35 to 7.45 and a PO2
greater than 150 mm Hg.
Extracorporeal circuit operation and sampling. 
After gaining approval from the Human Investigation
Committee of Yale University School of Medicine and
obtaining informed consent from the subjects, we drew blood
(500 mL) over a 5-minute period from healthy volunteers
who were receiving no medications. The blood was drawn
into a transfer pack (Baxter Healthcare Corp, Deerfield, Ill)
containing porcine heparin (5 U/mL final concentration).
Anti-C8 or control Mab was added to the transfer pack imme-
diately before addition of the blood to the extracorporeal cir-
cuit. As blood was introduced to the circuit reservoir, 400 mL
of prime fluid was simultaneously withdrawn to yield a final
circuit volume of 700 mL, a mean hematocrit value of 24% ±
4% (standard deviation), and a final Mab concentration of 40
m g/mL. Blood was gently and slowly circulated with prime,
and complete mixing was accomplished within 2 minutes;
this point was designated as time 0. The circuit flow rate was
then accelerated to 1.5 L/min, cooled to 27°C over 5 minutes,
and maintained at that temperature for 60 minutes. Then it
was rewarmed to 37°C for an additional 30 minutes (90 min-
utes of total recirculation time), simulating CPB at our insti-
tution. Six experiments were performed with anti-C8 Mab at
40 m g/mL and 4 with control Mab at the same final concen-
tration. Blood samples were drawn at 0, 5, 15, 30, 45, 60, 75,
and 90 minutes of recirculation. Plasma samples for C3a and
C5b-9 were immediately snap-frozen in liquid nitrogen and
stored at –70°C until assayed. Plasma samples for neutrophil
elastase-antitrypsin complex were anticoagulated with EDTA
and similarly snap-frozen. Whole blood samples for flow
cytometric studies were immediately fixed in 1% (final con-
centration) paraformaldehyde in phosphate-buffered saline
solution.17 Additional whole blood samples were drawn into
EDTA, 5 mmol/L, at 0, 30, and 90 minutes for a complete
blood count and leukocyte differential.
Flow cytometry. Whole blood samples were fixed for 60
minutes at 4°C followed by addition of 1:8 vol/vol of Tris-
glycine.18 Samples were washed twice and resuspended in
Tyrode-HEPES buffer, aliquots were incubated with fluores-
cent Mab at 4°C for 20 minutes, and then washed and resus-
pended in Tyrode-HEPES buffer for flow cytometric analysis.
The percentage of leukocytes with bound platelets and leuko-
cyte activation was determined by labeling samples with (1)
fluorescein isothiocyanate–anti-CD45 and phycoerythrin–
anti–glycoprotein IIb/IIIa and (2) fluorescein isothio-
cyanate–anti-CD45 and phycoerythrin–anti-CD11b, respec-
tively. Platelet CD62P expression was determined by labeling
with (3) fluorescein isothiocyanate–anti-glycoprotein IIb/IIIa
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and phycoerythrin–anti-CD62P.18 Samples were analyzed on
a FACScan flow cytometer (Becton-Dickinson, Mountain
View, Calif). Leukocyte measurements were carried out by
live-gating on fluorescein isothiocyanate–positive, leukocyte-
sized events, and PMN and monocyte populations were dis-
tinguished on the basis of size, granularity, and differential
CD45 expression.18 Mean CD11b fluorescence and the per-
centage of leukocyte-platelet conjugates were determined as
previously described.9 Platelet analysis was accomplished by
acquisition of fluorescein isothiocyanate–positive, platelet-
sized events with the percentage of platelets expressing
CD62P determined as previously described.18 An isotype-
matched control Mab was used to set a threshold (99% of
events below threshold) for CD62P expression and quantita-
tion of leukocyte-platelet conjugates.
Plasma assays. C3a and C5b-9 levels were measured by
enzyme-linked immunosorbent assay kits from Quidel (San
Diego, Calif) according to the methods described by the man-
ufacturer. Levels were reported in absorbance units (AU) as
in previous work.15 Neutrophil elastase levels were similarly
measured by enzyme-linked immunosorbent assay (E.M.
Sciences, Gibbstown, NJ) according to the manufacturer’s
instructions. 
Statistics. C3a and C5b-9 levels are reported as mean ±
standard error of the mean of the absolute values. All other
results are expressed as a percentage of the individual exper-
iment’s time 0 value to minimize the effect of interdonor vari-
ability. Thus changes over time of recirculation are expressed
as relative changes compared with the starting value and are
reported as mean ± standard error of the mean. Two-way
analysis of variance for time and antibody effect was per-
formed with GraphPad software (Prism, San Diego Calif).
Results
Complement activation. C3a and sC5b-9 levels
were nearly undetectable at baseline. Control SECC
(SECC with control Mab) resulted in significant com-
plement activation, with C3a rising from 0.002 ±
0.0001 AU to 0.553 ± 0.12 AU and sC5b-9 increasing
from 0.003 ± 0.001 AU to 0.39 ± 0.08 AU after 90 min-
utes of recirculation (Fig 1, A and B, P = .001 for both).
As expected, recirculation after addition of the anti-C8
Mab at 40 m g/mL did not block C3a generation (0.65 ±
0.14 AU at 90 minutes, P = .64, Fig 1, A). By contrast,
sC5b-9 formation was significantly reduced, albeit not
completely abrogated, by addition of the anti-C8 Mab,
reaching a peak at 90 minutes of 0.22 ± 0.037 AU (P =
.01 for anti-C8 vs control Mab, Fig 1, B). 
Platelet activation. The percentage of activated
(CD62P-positive) platelets increased significantly dur-
ing control SECC, peaking at 202% ± 52% of the base-
line value after 90 minutes of recirculation (P = .01).
Anti-C8 Mab addition abrogated this increase, with the
percentage of activated platelets peaking earlier during
SECC (at 15 minutes) and only reaching 125% ± 13% of
baseline (P = .001, Fig 2, A); the percentage of activated
platelets then decreased slightly during the remaining
time of recirculation. As another, perhaps more sensitive,
indicator of overall platelet activation,19 the increase in
circulating monocyte-platelet conjugates during SECC
was also significantly inhibited by C8 blockade, peaking
at 153% ± 9% of baseline at 90 minutes compared with
203% ± 51% for control Mab (Fig 2, B, P = .001). PMN-
platelet conjugates also formed during control SECC,
peaking at 306% ± 112% after 90 minutes of recircula-
tion (Fig 2, C). Inhibition of formation of PMN-platelet
conjugates by the anti-C8 Mab did not reach statistical
significance, with levels peaking at 234% ± 54% after 60
minutes of recirculation (P = .057). 
Cell counts. The platelet count during control SECC
was 130 · 103/m L ± 11 · 103/m L at time 0; platelet
Fig 1. C3a and C5b-9 during SECC. Levels of C3a (A) and
sC5b-9 (B) during SECC were measured in plasma samples
taken at the time points shown on the abscissa. The mean ±
standard error of the mean from 4 control experiments (l )
and 6 experiments with addition of the anti-C8 Mab at 40
mg/mL (u ) are shown. Anti-C8 significantly inhibited C5b-9
(B, P = .01) but not C3a (A, P = .64) generation. 
A
B
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Fig 2. CD62P-positive platelets and platelet-leukocyte conju-
gate formation during SECC. The percentage of circulating
CD62P-positive platelets (A), the percentage of monocytes
binding platelets (B), and the percentage of PMN binding
platelets (C) during SECC were measured in whole blood
samples taken at the time points shown on the abscissa and
expressed as a percentage of the time 0 value. The mean ±
standard error of the mean from 4 control experiments (u )
and 6 experiments with addition of the anti-C8 Mab at 40
m g/mL (d) are shown. Anti-C8 significantly inhibited the
increase in CD62P-positive platelets (P = .001) and the for-
mation of monocyte-platelet conjugates (P = .001) but not the




Fig 3. Platelet, monocyte, and PMN counts during SECC.
Platelet (A), monocyte (B), and PMN (C) counts during
SECC were measured in whole blood samples taken at the
time points shown on the abscissa and expressed as a per-
centage of the time 0 value. The mean ± standard error of the
mean from 4 control experiments (u ) and 6 experiments with
addition of the anti-C8 Mab at 40 m g/mL (d) are shown.
Anti-C8 significantly inhibited the decrease in platelets,
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counts decreased to a nadir of 55% ± 10% of the base-
line value after 30 minutes of recirculation and then
increased to 77% ± 6% with rewarming. This decrease
was completely inhibited by the anti-C8 Mab, begin-
ning with a platelet count of 133 · 103/m L ± 18 ·
103/m L at time 0 and falling to only 94% ± 8% of the
baseline value after 30 minutes of recirculation (P =
.01, Fig 3, A). Circulating monocytes also decreased
during control SECC, beginning recirculation at 373 ±
11 cells/m L and reaching a nadir of 25% ± 6% of base-
line after 90 minutes. Addition of Anti-C8 Mab pro-
duced significantly greater preservation of monocyte
counts, beginning recirculation at 315 ± 55 cells/m L
and falling to only 87% ± 25% after 90 minutes (P =
.01, Fig 3, B). Similarly, the anti-C8 Mab preserved
PMN counts during SECC, beginning with 2.1 · 103 ±
0.2 · 103 cells/m L and decreasing to a nadir of only
81% ± 3% of the baseline value (P = .01, Fig 3, C),
compared with a time 0 value of 3.2 · 103 ± .9 · 103
cells/m L and decreasing to 53% ± 6% over the same
period during control SECC.
Leukocyte activation. Control SECC activated both
PMNs and monocytes, with CD11b levels increasing to
251% ± 66% and 206% ± 36% of their baseline values,
respectively (P = .01 for both), similar to previous stud-
ies.10 Neutrophil elastase levels increased to 889% ±
614% of baseline values after 90 minutes of recircula-
tion (P = .01). Addition of the anti-C8 Mab to SECC
had no effect on leukocyte activation; neutrophil and
monocyte CD11b increased to 187% ± 14% and 191%
± 30%, respectively (P = .2 for both); similarly, neu-
trophil elastase levels rose to 812% ± 353% of the
baseline value (P = .50, Fig 4). 
Discussion
This investigation has demonstrated that selective
blockade of the C8 complement component successful-
ly decreases sC5b-9 formation during SECC.
Inhibition of MAC formation was associated with a
significant reduction in platelet activation as measured
by both the percentage of CD62P-positive platelets and
monocyte-platelet conjugate formation. Formation of
the latter complex is predominantly dependent on acti-
vation-induced platelet surface expression of CD62P,
an adhesive ligand for monocytes, and to a lesser
extent, PMN,9 and thus supports the conclusion that
platelet activation on SECC is primarily caused by
MAC formation. These findings are also consistent
with the in vitro demonstration of C5b-9–induced
CD62P expression.20 Furthermore, abrogation of the
decline in the number of circulating platelets during
SECC by anti-C8 is likely also a result of reduced
Fig 4. Leukocyte activation during SECC. Peak expression of CD11b on monocytes and PMNs in whole blood
samples (left axis) and the PMN elastase in plasma (right axis) are expressed as a percentage of the time 0 value.
The mean ± standard error of the mean from 4 control experiments (solid bars) and 6 experiments with addition
of the anti-C8 Mab at 40 m g/mL (hatched bars) are shown. Anti-C8 did not inhibit the increase in monocyte
CD11b, PMN CD11b, or PMN elastase (P = .15 for all) during SECC. 
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platelet activation. The role of temperature in MAC-
induced platelet activation was not directly examined in
this study; however, the increases in circulating
CD62P-positive platelets and monocyte-platelet conju-
gates occurring early during the hypothermic phase of
control SECC support the finding21 that hypothermia
does not abrogate the stimulatory effects of CPB on
adhesion molecules.
In contrast to platelet activation, selective blockade of
MAC formation did not inhibit either monocyte or
PMN activation, as measured by up-regulation of the
adhesion receptor CD11b and neutrophil elastase
release. Complement activation, along with contact
activation–induced mediators, for example,
kallikrein,22 contributes to the generalized inflammato-
ry response to CPB, but the link between specific com-
plement components and cellular activation pathways
has been difficult to ascertain. Previous work from our
laboratory demonstrated that anti-C5 blockade on
SECC inhibited C5a and C5b-9 formation but did not
check C3a formation. In addition to inhibiting platelet
activation and formation of platelet-leukocyte conju-
gates, blockade of both C5a and C5b-9 formation pre-
vented PMN activation. By contrast, in the current
study, selective C5b-9 inhibition did not affect PMN
activation. These data suggest that C5a, rather than
C5b-9, is responsible for the complement-related PMN
activation induced by SECC. This is consistent with in
vitro studies in which C5a is a potent activator of
PMN.11 The effects of C5b-9 on leukocytes appear to
be more subtle. Nucleated cells are relatively resistant
to the lytic effects of complement membrane attack23;
however, nonlytic C5b-9 levels can induce release of
reactive oxygen metabolites from PMNs,24 creating the
potential for additional proinflammatory effects. These
latter effects, however, may not be detectable in the set-
ting of the more profound levels of PMN activation
induced when C5a formation is unopposed, as in the
present study.
It is important to note one caveat: because we were
unable to completely abrogate C5b-9 formation, it
remains possible, albeit unlikely, that the small amounts
of C5b-9 produced in the presence of the anti-C8 Mab
were sufficient to activate PMNs. The incomplete block-
ade of MAC may be a function of the particular Mab
used or may be a universal finding with any inhibitor of
C8 cleavage. The Mab dosage did not appear to be the
limiting factor, given that doubling the anti-C8 dose did
not additionally improve MAC inhibition (data not
shown). Therefore, although these results demonstrate
that inhibition of platelet activation by terminal comple-
ment blockade is predominantly caused by C5b-9 rather
than C5a, it is not possible to determine whether C5b-9
generation contributes in more subtle ways to PMN acti-
vation. Nevertheless, on the basis of the ability of in vitro
C5a to potently activate PMNs,11 and the current find-
ings, we believe C5a to be one of the major inducers of
PMN activation in the SECC setting. Blockade of C5a
formation and contact activation–induced kallikrein pro-
duction are promising strategies for reducing the inflam-
matory response to CPB.
MAC inhibition also preserved the total number of
circulating platelets, monocytes, and PMNs compared
with control Mab runs. Although we expected that
reduced platelet activation would limit platelet adhe-
sion to the circuit25 and preserve platelet numbers, the
surprisingly effective preservation of leukocyte counts,
despite continued leukocyte activation, may suggest
important features of the pathophysiology of leuko-
cyte-biomaterial interaction. Preservation of the
absolute numbers of circulating leukocytes could be an
indirect result of reduced platelet activation in the pres-
ence of MAC inhibition. Data from our laboratory and
others26,27 have suggested that leukocyte adhesion to a
biomaterial surface can occur as the result of “bridg-
ing” by platelets bound both to the material and to
leukocytes. Fibrinogen binds rapidly to the CPB cir-
cuit; activated platelets may adhere to the bound fib-
rinogen via glycoprotein IIb/IIIa27; monocytes and
PMNs may then bind via CD62P to these platelets and
consequently be lost to the circulation. Since circulat-
ing platelet-leukocyte conjugates were reduced by anti-
C8, it is possible that a similar event occurs on the cir-
cuit itself, although other explanations such as
decreased mediator release by activated platelets are
also possible.
It is not known whether selective inhibition of C5b-9
formation would be of benefit in clinical settings neces-
sitating extracorporeal circulation. In theory, specific
inhibition of platelet activation by the MAC may reduce
procoagulant activity in the perioperative period,
because MAC assembly on the platelet surface causes
phosphatidylserine exposure, produces procoagulant
platelet microparticles,6 and enhances platelet “proco-
agulant activity” in vitro.20 The activated platelet may
also increase monocyte procoagulant activity through
CD62P-mediated induction of tissue factor.28 Thus
selective inhibition of MAC formation might be appro-
priate for circumstances in which it is desirable for
PMNs to remain responsive to complement, but at the
same time limiting the procoagulant potential of
platelets and monocyte-platelet conjugates. In the set-
ting of CPB, however, the additional reduction of proin-
flammatory PMNs through complement and/or contact
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pathway inhibition is desirable to reduce “reperfusion
injury” physiology. Blockade at C5b-9 alone is not like-
ly to block this physiology and has the potential to
worsen any inflammatory component by preserving
greater numbers of activated PMNs in the circulation. 
In summary, selective inhibition of C5b-9 generation
during SECC resulted in significant inhibition of
platelet activation and activation-dependent monocyte-
platelet conjugate formation. This inhibition also
allowed greater preservation of absolute numbers of
circulating platelets, as well as PMNs and monocytes.
By contrast, C5b-9 inhibition did not produce any
decrease in PMN or monocyte activation, suggesting at
best a minor role for this complement component in
leukocyte activation during SECC. This study also sug-
gests that platelet activation and/or MAC may be
responsible in part for the loss of circulating PMNs and
monocytes to the extracorporeal circuit.
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